Fernández, Mario I.
Brausi, Maurizio
Clark, Peter E.
Cookson, Michael S.
Grossman, H. Barton
Khochikar, Makarand
Kiemeney, Lambertus A.
Malavaud, Bernard
Sanchez-Salas, Rafael
Soloway, Mark S.
Svatek, Robert S.
Vikram, Raghunandan
Vrieling, Alina
Kamat, Ashish M.
Funding for this research was provided by:
Raymond & Maria Floyd Bladder Cancer Research (111306)
Duddlesten Sr. Professorship (116390)
Article History
Received: 25 May 2018
Accepted: 6 August 2018
First Online: 13 August 2018
Compliance with ethical standards
:
: MCookson has received personal fees from Jansenn Biotech, MDxHealth, Astellas Pharma, Bayer, Genomic Health, Carden Jennings, Abbott, and Altor. HB Grossman has received personal fees from Abbott Molecular, Cepheid, and Nucleix. A Kamat is a consultant to the following companies; TMC Innovation, Merck, BMS, Arquer, MDxHealth, Photocure, Theralase, Cepheid, Medac, Asieris, Pfizer, and Astra Zeneca and has received research funding from FKD, Merck, Telesta, and Adolor. In addition, A Kamat has a patent CyPRIT—Cytokine Panel for Response to Intravesical Immunotherapy pending. The rest of the authors declare that they have no conflict of interest.
: This article does not contain any studies with human participants or animals performed by any of the authors.
: Informed consent was not required, since this article does not contain any studies with human participants.